The central role of the intestinal microbiota in the progression and, equally, prevention of
metabolic dysfunction is becoming abundantly apparent. The symbiotic relationship …

Aims To compare efficacy and safety of glucagon‐like peptide‐1 receptor agonists (GLP‐
1RAs) in people with type 2 diabetes. Materials and methods We electronically searched, up …

Obesity poses a severe threat to human health, including the increased prevalence of
hypertension, insulin resistance, diabetes mellitus, cancer, inflammation, sleep apnoea and …

The gastrointestinal tract—the largest endocrine network in human physiology—
orchestrates signals from the external environment to maintain neural and hormonal control …

The prevalence of type 2 diabetes is increasing at an astounding rate. Many of the agents
used to treat type 2 diabetes have undesirable adverse effects of hypoglycemia and weight …

This review focuses on the contribution of white, brown, and perivascular adipose tissues to
the pathophysiology of obesity and its associated metabolic and vascular complications …

The progressive nature of type 2 diabetes (T2D) requires practitioners to periodically
evaluate patients and intensify glucose-lowering treatment once glycemic targets are not …

What is known and objective Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are
one of the preferred approved treatment options for people with type 2 diabetes (T2D) and …

Background Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-
1 receptor agonists (GLP-1RA) lower blood pressure (BP). When SGLT2i and GLP-1RA are …

In early childhood, individuals with Prader‐Willi syndrome (PWS) experience excess weight
gain and severe hyperphagia with food compulsivity, which often leads to early onset morbid …